Mineralys Therapeutics, Inc. MLYS Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -31%+25.3pp | -36.9%+45.3pp | -42.1%+19.0pp | -63.2%-21.6pp | -56.3%-27.2pp | |
| Liquidity | ||||||
| Current ratio | 44.3×+17.8× | 43.8×+29.7× | 25.5×+17.0× | 15.1×+3.9× | 26.5×+8.4× | |
| Per Share | ||||||
| Book value per share | $7.70+19.9% | $9.56+143% | $8.17+71.7% | $4.79-18.5% | $6.42-12.1% | |
| Valuation | ||||||
| Market capitalization | $2.23B+124% | $2.87B+369% | $2.94B+392% | $921.58M+75.4% | $997.24M+92.7% | |
| Price / book | 3.5×+0.6× | 4.4×+1.2× | 5.1×+2.6× | 2.9×+1.1× | 2.9×+1.3× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Mineralys Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Mineralys Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.